In patients with prostate cancer who have undergone a prostatectomy followed by radiotherapy, 24 months of androgen deprivation therapy (ADT) increases metastasis-free survival (MFS) relative to shorter courses or no ADT, according to a trial with multiple randomizations and long-term follow-up.
The findings were reported at the 2022 annual meeting of the European Society for Medical Oncology (ESMO) (abstract LBA 9). The data address an unanswered question, according to Chris C. Parker, MD, a